User:Mr. Ibrahem/Velaglucerase alfa

Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for Gaucher disease type 1. It is given by gradual injection into a vein every two weeks. Effectiveness is similar to imiglucerase.

Common side effects include abdominal pain, headache, dizziness, bone pain, infusion-related reactions, tiredness, and fever. Antibodies against the medication may form. It works by replacing the missing enzyme glucocerebrosidase and thus facilitating the breakdown of glucocerebroside.

Velaglucerase alfa was approved for medical use in Europe and the United States in 2010. In the United Kingdom 400 units costs the NHS about £1,400 as of 2021. This amount in the United States costs about 1,500 USD. In Canada for a typical 70 kg individual the medication costs about 150,000 to 560,000 CAD a year as of 2017. It is made by recombinant DNA techniques.